封面
市场调查报告书
商品编码
1300980

药物警戒市场规模、份额和趋势分析报告:按服务提供商、产品生命週期、治疗领域、工艺流程、最终用途、产品类型和细分市场预测,2023-2030 年

Pharmacovigilance Market Size, Share & Trends Analysis Report By Service Provider (In-house, Contract Outsourcing), By Product Life Cycle, By Therapeutic Area, By Process Flow, By End-Use, By Type, And Segment Forecasts, 2023 - 2030

出版日期: | 出版商: Grand View Research | 英文 298 Pages | 商品交期: 2-10个工作天内

价格

药物警戒市场增长和趋势

预计到 2030 年,全球药物警戒市场将达到 118 亿美元。

预计在预测期内復合年增长率为 7.0%。 市场增长的主要驱动力是副作用(ADR)发生率的增加。 ADR 给医疗保健系统带来沉重负担,是发达国家最明显的发病来源之一。 根据美国国家生物技术信息中心 (NCBI) 的数据,在欧洲,每年因 ADR 住院的患者中约有二十分之一。 药物警戒 (PV) 服务通过协助製造商在临床试验阶段识别与药物相关的不良反应发挥着重要作用。

此外,根据2022年2月发表在《当代医学研究与实践杂誌》上的文章《接受癌症化疗药物的患者药物不良反应的严重性和结果——一项前瞻性观察研究》文章显示,严重的ADR每年导緻美国超过10万人死亡,成为过去十年来最严重的健康问题。 致命性心律失常和肝功能衰竭等不良反应可能会导致药物从市场上撤出,因为与药物使用相关的风险超过了相关的益处。 COVID-19大流行对光伏服务提供商来说既是机遇也是挑战,需要开发创新平台以提高其竞争力。

例如,2020 年 12 月,生命科学行业商业服务提供商 EVERSANA 与专门从事药物开发流程自动化的生命科学软件公司 ArisGlobal 合作。 该合作伙伴关係旨在将端到端 PV 程序数字化,以在全球范围内实现更安全、更有效的医疗保健。 技术先进且用户友好的软件系统市场(例如基于云的光伏和药物安全平台)预计将在预测期内支持该行业的增长。 例如,Clinevo Technologies 提供 Clinevo Safety,这是一种基于云的解决方案,涵盖案例处理、监管提交/AS2 网关、PV 摄入、分析、安全信号等。

这个一体化平台正在引领市场。 此外,协调一致的努力正在支持巴西等新兴市场的增长。 例如,巴西推出了涉及製药行业、学术界、临床实践和卫生当局的患者安全和 PV 计划。 该项目由 FIPFARMA(Fundacao Instituto de Pesquisas Farmaceuticas)和药学院(圣保罗大学)提供,分两批(2020 年和 2022 年)提供了 30 小时的在线课程。 该课程涵盖了医疗保健和药物警戒概述、药物安全和管理以及患者安全文化等重要主题。 该研讨会解决了医疗保健专业人员 (HCP) 面临的现实挑战,并鼓励协作解决问题。

视频会议有效地吸引了 HCP 并对其进行了教育,促进了知识共享,并促进了思维方式的转变。 该倡议对参与者产生了积极影响,并加强了巴西的光伏实践。 发达国家领先的製药公司正在重点外包光伏服务,以降低成本并减少运营费用。 预计这将为发展中国家的合同研究组织(CRO)创造扩大其行业份额的机会。 製造商正在重新考虑他们的产品开发程序,以满足全球患者不断增长的需求。 由于这些因素,预计在预测期内对光伏服务的需求将会扩大。

此外,光伏行业的公司正在实施收购、合作、业务扩张和产品发布等战略,以扩大其产品范围并提高其在市场上的影响力。 例如,专门从事製药行业的服务提供商 Ergomed plc 于 2022 年 2 月收购了 ADAMAS Consulting Group Limited。 ADAMAS 是一家提供药品製造、临床试验审核和光伏系统质量保证服务的国际咨询公司。 此次交易价值 2560 万英镑,预计将为 Ergomed 带来盈利,并在未来提供进一步的增长和战略优势。

药物警戒市场报告亮点

  • 第四阶段占据市场主导地位,到 2022 年销售份额将超过 75%。 这是由于 ADR 事件和上市后监督的增加。
  • 随着製药公司寻求通过外包服务降低运营成本,2022 年合同外包将占据服务提供商细分市场 60% 以上的市场份额。
  • 自愿报告细分市场在 2022 年以超过 30% 的销售份额引领市场。 其应用包括高效且经济高效地检测新型、严重和罕见的 ADR。
  • 在生物製药公司在慢性癌症治疗方面的研究努力的推动下,肿瘤学在 2022 年占据治疗领域的最大份额,超过 25%。
  • 预计在预测期内,流程领域的案例数据管理将以 7.3% 的最快复合年增长率增长。
  • 生物技术公司在最终用途领域的复合年增长率将达到 8.0%,是最快的。 这是因为我们专注于生物製剂、治疗药物和基因治疗等新产品的研发。
  • 由于对新药开发的投资、有利的监管以及在研究单位和临床试验方面的强大影响力,北美在 2022 年占据了最大的收入份额,超过 30%。
  • 公司采用新产品发布、合作伙伴关係和收购等策略来获得竞争优势。

内容

第一章调查方法及范围

  • 市场细分和范围
  • 调查方法
  • 信息获取
  • 信息或数据分析
  • 市场形成和验证
  • 型号详细信息
  • 辅助信息列表
  • 缩写列表
  • 市场定义
  • 报告的目的

第 2 章执行摘要

第 3 章药物警戒市场变量、趋势和范围

  • 市场体系展望
    • 母公司市场分析
    • 补充市场分析
  • 采用和增长前景图
  • 药物警戒市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
    • 行业问题
  • 药物警戒市场分析工具:Porter
  • SWOT 分析,按因素(政治/法律、经济、技术)
  • 价值链分析
    • 临床前
    • 临床
    • PMA
  • 服务产品及其需求的生命週期映射
  • 监管框架
    • 按国家/地区划分的监管机构列表
  • 组织结构简介
  • 定价模型
    • 按活动分配药品安全预算
    • 按开发阶段划分
    • 按治疗领域
    • 价格水平
  • 技术时间表概述
    • 不断变化的技术和采用
  • 新冠肺炎 (COVID-19) 的影响
    • 近期发展和战略成就
    • 公司实施的战略
  • 市场趋势
    • 资源扩展
    • 药物警戒自动化
  • 通货膨胀的影响
  • 医学写作与医疗安全审查的比较分析
    • 2022 年医学写作市场展望
    • 2022 年医疗安全审查市场展望

第 4 章药物警戒市场:产品生命週期估算和趋势分析

  • 2022 年和 2030 年市场份额分析
  • 仪表板
  • 市场定义和范围
    • 临床前
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段

第五章药物警戒市场:服务提供商的估算和趋势分析

  • 2022 年和 2030 年市场份额分析
  • 仪表板
  • 市场定义和范围
    • 内部
    • 合同工作外包

第 6 章药物警戒市场:类型估计和趋势分析

  • 2022 年和 2030 年市场份额分析
  • 仪表板
  • 市场定义和范围
    • 自愿报告
    • 增强的 ADR 报告
    • 有针对性的自愿报告
    • 群组事件监控 (CEM)
    • 电子病历挖矿

第 7 章药物警戒市场:工艺流程估计和趋势分析

  • 2022 年和 2030 年市场份额分析
  • 仪表板
  • 市场定义和范围
    • 案例数据管理
    • 信号检测
    • 风险管理体系

第八章药物警戒市场:治疗领域预估及趋势分析

  • 2022 年和 2030 年市场份额分析
  • 仪表板
  • 市场定义和范围
    • 肿瘤
    • 神经
    • 心脏病学
    • 呼吸系统
    • 其他

第 9 章药物警戒市场:最终用途估计和趋势分析

  • 2022 年和 2030 年市场份额分析
  • 仪表板
  • 市场定义和范围
    • 药品
    • 生物科技公司
    • 医疗器械製造商
    • 其他

第 10 章药物警戒市场:按地区、按产品、按服务提供商、按类型和最终用途进行估算和趋势分析

  • 区域市场快照
  • 北美
    • 2018-2030 年北美药物警戒市场估计和预测
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲药物警戒市场估计和预测
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 俄罗斯
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 2018-2030 年亚太地区药物警戒市场估算和预测
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲药物警戒市场估计和预测
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 2018-2030 年中东和非洲药物警戒市场估计和预测
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第 11 章药物警戒市场:竞争分析

  • 市场参与分类
  • 上市公司
    • 企业市场分析
    • 公司市场份额
  • 私人公司
    • 主要初创企业名单
  • 战略合作和增加产品发布
  • 政府战略举措,包括合作
  • 竞争对手加强光伏意识计划
  • 竞争对手加强合作和运营外包
  • 整合趋势
  • 潜在客户

第12章竞争格局

  • 公司简介
    • ACCENTURE
    • CLINQUEST GROUP BV(LINICAL AMERICAS)
    • IQVIA
    • COGNIZANT
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • IBM CORPORATION
    • ARISGLOBAL
    • ICON PLC.
    • CAPGEMINI
    • ITCLINICAL
    • TAKE SOLUTIONS LIMITED
    • PAREXEL INTERNATIONAL CORPORATION.
    • BIOCLINICA, INC.
    • WIPRO
    • UNITED BIOSOURCE LLC
    • FMD K&L(CLINCHOICE)

第 13 章成功策略

第 14 章转换成本分析

Product Code: 978-1-68038-327-0

Pharmacovigilance Market Growth & Trends

The global pharmacovigilance market size is projected to reach USD 11.8 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 7.0% during the forecast period. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights

  • Phase IV dominated the market with a revenue share of over 75% in 2022. This was driven by increased ADR incidents and post-marketing surveillance
  • Contract outsourcing accounted for over 60% market share in the service provider segment in 2022, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
  • The spontaneous reporting type segment led the market with a revenue share of over 30% in 2022. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
  • Oncology held the largest share of over 25% in the therapeutic area segment in 2022, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
  • Case data management is anticipated to grow at the fastest CAGR of 7.3% in the process flow segment during the forecast period
  • Biotechnology companies are expected to have the fastest CAGR of 8.0% in the end-use segment. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
  • North America held the largest revenue share of over 30% in 2022 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
  • Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Product Life Cycle
    • 1.1.2 Service Provider
    • 1.1.3 Type
    • 1.1.4 Process Flow
    • 1.1.5 Therapeutic Area
    • 1.1.6 End-Use
    • 1.1.7 Regional Scope
    • 1.1.8 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database:
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details Of Primary Research
      • 1.3.5.1 Data For Primary Interviews In North America
      • 1.3.5.2 Data For Primary Interviews In Europe
      • 1.3.5.3 Data For Primary Interviews In Apac
      • 1.3.5.4 Data For Primary Interviews In Latin America
      • 1.3.5.5 Data For Primary Interviews In Mea
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Top Down Market Estimation
      • 1.6.1.2 Cagr Calculation
      • 1.6.1.3 Key Report Updates
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Abbreviations
  • 1.9 Market Definitions
  • 1.10 Report Objectives
    • 1.10.1 Objective 1:
    • 1.10.2 Objective 2:

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot (Product Life Cycle & Service Provider)
  • 2.3 Segment Snapshot (Type & Therapeutic Area)
  • 2.4 Segment Snapshot (Process Flow & End Use)
  • 2.5 Competitive Landscape Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Analysis
    • 3.1.2 Ancillary Market Analysis
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Pharmacovigilance Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Growing Drug Consumption And Drug Development Rates
      • 3.3.1.2 Increasing Incidence Of Adr And Drug Toxicity
      • 3.3.1.3 Increasing Trend Of Outsourcing Pharmacovigilance Services
      • 3.3.1.4 Increasing Externalization Of Clinical Trial Studies By Large Pharmaceutical And Biopharmaceutical Companies
      • 3.3.1.5 Increasing Regulatory Burden On Manufacturers
      • 3.3.1.6 Introduction Of Technologically Advanced Software Services
      • 3.3.1.7 Constantly Rising Investment On R&D By Healthcare Companies
      • 3.3.1.8 Partnerships And Collaborations Between Market Players
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Shortage Of Skilled Labor
      • 3.3.2.2 Expensive Technology For Small And Mid-Sized Player
      • 3.3.2.3 Lack Of Recognition
      • 3.3.2.4 Scarcity Of Integration Standards
    • 3.3.3 Industry Challenges
  • 3.4 Pharmacovigilance Market Analysis Tools: Porters
  • 3.5 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
  • 3.6 Value Chain Analysis
    • 3.6.1 Preclinical
    • 3.6.2 Clinical
    • 3.6.3 PMA
  • 3.7 Mapping of Life Cycle against Service Offering and Their Demand
  • 3.8 Regulatory Framework
    • 3.8.1 List Of Regulatory Bodies By Country
  • 3.9 Organization Structure Introduction
  • 3.10 Pricing Models
    • 3.10.1 Drug Safety Budget Allocation By Activities
    • 3.10.2 By Development Phase
    • 3.10.3 By Therapeutic Area
    • 3.10.4 Pricing Level
      • 3.10.4.1 Project Management
      • 3.10.4.2 Case Processing
      • 3.10.4.3 Adr Reporting
      • 3.10.4.4 Medical Writing
      • 3.10.4.5 Drug Safety Management
  • 3.11 Technology Timeline Overview
    • 3.11.1 Changing Technology & Adoption
      • 3.11.1.1 Social Media
      • 3.11.1.2 Literature Screening
      • 3.11.1.3 Automation And Ai
      • 3.11.1.4 Big Data Analytics In Pv
  • 3.12 Impact Of Covid-19
    • 3.12.1 Recent Developments & Strategic Outcomes
      • 3.12.1.1 Regulatory Requirements/Changes Due To Covid-19
    • 3.12.2 Strategies Implemented By Companies
      • 3.12.2.1 Iqvia
      • 3.12.2.2 Paraxel International Corporation
      • 3.12.2.3 Bioclinica
      • 3.12.2.4 Pharmaceutical Product Development (Ppd)
      • 3.12.2.5 Ibm Corporation
      • 3.12.2.6 Icon, Plc
      • 3.12.2.7 Pra Health Sciences
      • 3.12.2.8 Covance Inc
      • 3.12.2.9 Arisglobal
      • 3.12.2.10 Linical Accelovance
      • 3.12.2.11 Laboratory Corporation Of America Holdings
  • 3.13 Market Trends
    • 3.13.1 Scaling Of Resources
    • 3.13.2 Automation In Pharmacovigilance
  • 3.14 Impact Of Inflation
  • 3.15 Comparative Analysis Between Medical Writing Vs Medical Safety Review
    • 3.15.1 Medical Writing Market Outlook, 2022
      • 3.15.1.1 Medical Writing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 3.15.2 Medical Safety Review Market Outlook, 2022
      • 3.15.2.1 Medical Safety Review Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

  • 4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
  • 4.2 Product Life Cycle Dashboard
  • 4.3 Market Definition And Scope
    • 4.3.1 Preclinical
      • 4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.2 PHASE I
      • 4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.3 PHASE II
      • 4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.4 PHASE III
      • 4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.3.5 PHASE IV
      • 4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

  • 5.1 Service provider Market Share Analysis, 2022 & 2030
  • 5.2 Service Provider Dashboard
  • 5.3 Market definition and scope
    • 5.3.1 In House
      • 5.3.1.1 In House Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2 Contract Outsourcing
      • 5.3.2.1 Contract Outsourcing Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

  • 6.1 Type Market Share Analysis, 2022 & 2030
  • 6.2 Type Dashboard
  • 6.3 Market definition and scope
    • 6.3.1 Spontaneous Reporting
      • 6.3.1.1 Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2 Intensified Adr Reporting
      • 6.3.2.1 Intensified Adr Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3 Targeted Spontaneous Reporting
      • 6.3.3.1 Targeted Spontaneous Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4 Cohort Event Monitoring (CEM)
      • 6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.5 EHR Mining
      • 6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

  • 7.1 Process Flow Market Share Analysis, 2022 & 2030
  • 7.2 Process Flow Dashboard
  • 7.3 Market definition and scope
    • 7.3.1 Case Data Management
      • 7.3.1.1 Case Data Management Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.1 Case Logging
      • 7.3.1.1.1.1 Case Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.2 Case data analysis
      • 7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
      • 7.3.1.1.3 Medical reviewing and reporting
      • 7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 Signal Detection
      • 7.3.2.1 Signal Detection Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.1 Adverse Event Logging
      • 7.3.2.1.1.1 Adverse Event Logging Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.2 Adverse Event Analysis
      • 7.3.2.1.2.1 Adverse Event Analysis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.1.3 Adverse Event Review & Reporting
      • 7.3.2.1.3.1 Adverse Event Review & Reporting Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3 Risk Mamangement System
      • 7.3.3.1 Risk Management System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.1 Risk Evaluation System
      • 7.3.3.1.1.1 Risk Evaluation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.1.2 Risk Mitigation System
      • 7.3.2.1.2.1 Risk Mitigation System Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

  • 8.1 Therapeutic Area Market Share Analysis, 2022 & 2030
  • 8.2 Therapeutic Area Dashboard
  • 8.3 Market definition and scope
    • 8.3.1 Oncology
      • 8.3.1.1 Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.2 Neurology
      • 8.3.2.1 Neurology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Cardiology
      • 8.3.3.1 Cardiology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 Respiratory Systems
      • 8.3.4.1 Respiratory Systems Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.3.5 Others
      • 8.3.5.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: End-Use Estimates & Trend Analysis

  • 9.1 End-Use Market Share Analysis, 2022 & 2030
  • 9.2 End-Use Dashboard
  • 9.3 Market definition and scope
    • 9.3.1 Pharmacuticals
      • 9.3.1.1 Pharmaceuticals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.2 Biotechnology Companies
      • 9.3.2.1 Biotechnology Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.3 Medical Device Manufacturers
      • 9.3.3.1 Medical Device Manufacturers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.3.4 Others
      • 9.3.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, And End-Use

  • 10.1 Regional Market Snapshot
  • 10.2 North America
    • 10.2.1 North America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.2.2 U.S.
      • 10.2.2.1 U.S. Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.2.2.2 Competitive Scenario
      • 10.2.2.3 Regulatory Framework
    • 10.2.3 Canada
      • 10.2.3.1 Canada Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.2.3.2 Competitive Scenario
      • 10.2.3.3 Regulatory Framework
  • 10.3 Europe
    • 10.3.1 Europe Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2 UK
      • 10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030(USD Million)
      • 10.3.2.2 Competitive scenario
      • 10.3.2.3 Regulatory Framework
    • 10.3.3 Germany
      • 10.3.3.1 Germany Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million
      • 10.3.3.2 Competitive Scenario
      • 10.3.3.3 Regulatory Framework
    • 10.3.4 France
      • 10.3.4.1 France Pharmacovigilance Market Estimates And Forecasts, 2018- 2030 (USD Million)
      • 10.3.4.2 Competitive Scenario
      • 10.3.4.3 Regulatory Framework
    • 10.3.5 Italy
      • 10.3.5.1 Italy Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.3.5.2 Competitive Scenario
      • 10.3.5.3 Regulatory Framework
    • 10.3.6 Spain
      • 10.3.6.1 Spain Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.3.6.2 Competitive Scenario
      • 10.3.6.3 Regulatory Framework
    • 10.3.7 Russia
      • 10.3.7.1 Russia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030 (USD Million)
      • 10.3.7.2 Competitive Scenario
      • 10.3.7.3 Regulatory Framework
    • 10.3.8 Denmark
      • 10.3.8.1 Denmark Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
      • 10.3.8.2 Competitive Scenario
      • 10.3.8.3 Regulatory Framework
    • 10.3.9 Norway
      • 10.3.9.1 Norway Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
      • 10.3.9.2 Competitive Scenario
      • 10.3.9.3 Regulatory Framework
    • 10.3.10 Sweden
      • 10.3.10.1 Sweden Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030, (USD Million)
      • 10.3.10.2 Competitive Scenario
      • 10.3.10.3 Regulatory Framework
  • 10.4 Asia Pacific
    • 10.4.1 Asia Pacific Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2 Japan
      • 10.4.2.1 Japan Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.2.2 Competitive Scenario
      • 10.4.2.3 Regulatory Framework
    • 10.4.3 China
      • 10.4.3.1 China Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.3.2 Competitive Scenario
      • 10.4.3.3 Regulatory Framework
    • 10.4.4 India
      • 10.4.4.1 India Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.4.2 Competitive Scenario
      • 10.4.4.3 Regulatory Framework
    • 10.4.5 Australia
      • 10.4.5.1 Australia Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.5.2 Competitive Scenario
      • 10.4.5.3 Regulatory Framework
    • 10.4.6 Thailand
      • 10.4.6.1 Thailand Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.6.2 Competitive Scenario
      • 10.4.6.3 Regulatory Framework
    • 10.4.7 South Korea
      • 10.4.7.1 South Korea Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.4.7.2 Competitive Scenario
      • 10.4.7.3 Regulatory Framework
  • 10.5 Latin America
    • 10.5.1 Latin America Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2 Brazil
      • 10.5.2.1 Brazil Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.2.2 Competitive Scenario
      • 10.5.2.3 Regulatory Framework
    • 10.5.3 Mexico
      • 10.5.3.1 Mexico Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.3.2 Competitive Scenario
      • 10.5.3.3 Regulatory Framework
    • 10.5.4 Argentina
      • 10.5.4.1 Argentina Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.5.4.2 Competitive Scenario
      • 10.5.4.3 Regulatory Framework
  • 10.6 MEA
    • 10.6.1 MEA Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2 South Africa
      • 10.6.2.1 South Africa Pharmacovigilance Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 10.6.2.2 Competitive Scenario
      • 10.6.2.3 Regulatory Framework
    • 10.6.3 Saudi Arabia
      • 10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.6.3.2 Competitive Scenario
      • 10.6.3.3 Regulatory Framework
    • 10.6.4 UAE
      • 10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.6.4.2 Competitive Scenario
      • 10.6.4.3 Regulatory Framework
    • 10.6.5 Kuwait
      • 10.6.5.1 Kuwait Pharmacovigilance Market Estimates And Forecasts, 2018- 2030(USD Million)
      • 10.6.5.2 Competitive Scenario
      • 10.6.5.3 Regulatory Framework

Chapter 11 Pharmacovigilance Market: Competitive Analysis

  • 11.1 Market Participation Categorization
  • 11.2 Public Companies
    • 11.2.1 Company Market Position Analysis
    • 11.2.2 Company Market Share
  • 11.3 Private Companies
    • 11.3.1 List Of Key Emerging Companies
  • 11.4 Increasing strategic collaborations and product launch
  • 11.5 Strategic Government initiatives which include collaborations
  • 11.6 Competitors increased PV awareness program
  • 11.7 Competitors increased collaboration and outsourcing of operations
  • 11.8 Consolidation Trends
  • 11.9 Potential Customers

Chapter 12 Competitive Landscape

  • 12.1 Company Profiles
    • 12.1.1 ACCENTURE
      • 12.1.1.1 Company overview
      • 12.1.1.2 Service benchmarking
      • 12.1.1.3 Financial performance
      • 12.1.1.4 Strategic initiatives
      • 12.1.1.5 SWOT Analysis
    • 12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
      • 12.1.2.1 Company overview
      • 12.1.2.2 Service benchmarking
      • 12.1.2.3 Financial performance
      • 12.1.2.4 Strategic initiatives
      • 12.1.2.5 SWOT Analysis
    • 12.1.3 IQVIA
      • 12.1.3.1 Company overview
      • 12.1.3.2 Service benchmarking
      • 12.1.3.3 Financial performance
      • 12.1.3.4 Strategic initiatives
      • 12.1.3.5 SWOT Analysis
    • 12.1.4 COGNIZANT
      • 12.1.4.1 Company overview
      • 12.1.4.2 Service benchmarking
      • 12.1.4.3 Financial performance
      • 12.1.4.4 Strategic initiatives
      • 12.1.4.5 SWOT Analysis
    • 12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 12.1.5.1 Company overview
      • 12.1.5.2 Service benchmarking
      • 12.1.5.3 Financial performance
      • 12.1.5.4 Strategic initiatives
      • 12.1.5.5 SWOT Analysis
    • 12.1.6 IBM CORPORATION
      • 12.1.6.1 Company overview
      • 12.1.6.2 Service benchmarking
      • 12.1.6.3 Financial performance
      • 12.1.6.4 Strategic initiatives
      • 12.1.6.5 SWOT Analysis
    • 12.1.7 ARISGLOBAL
      • 12.1.7.1 Company overview
      • 12.1.7.2 Service benchmarking
      • 12.1.7.3 Financial performance
      • 12.1.7.4 Strategic initiatives
      • 12.1.7.5 SWOT Analysis
    • 12.1.8 ICON PLC.
      • 12.1.8.1 Company overview
      • 12.1.8.2 Service benchmarking
      • 12.1.8.3 Financial performance
      • 12.1.8.4 Strategic initiatives
      • 12.1.8.5 SWOT Analysis
    • 12.1.9 CAPGEMINI
      • 12.1.9.1 Company overview
      • 12.1.9.2 Service benchmarking
      • 12.1.9.3 Financial performance
      • 12.1.9.4 Strategic initiatives
      • 12.1.9.5 SWOT Analysis
    • 12.1.10 ITCLINICAL
      • 12.1.10.1 Company overview
      • 12.1.10.2 Service benchmarking
      • 12.1.10.3 Financial performance
      • 12.1.10.4 Strategic initiatives
      • 12.1.10.5 SWOT Analysis
    • 12.1.11 TAKE SOLUTIONS LIMITED
      • 12.1.11.1 Company overview
      • 12.1.11.2 Service benchmarking
      • 12.1.11.3 Financial performance
      • 12.1.11.4 Strategic initiatives
      • 12.1.11.5 SWOT Analysis
    • 12.1.12 PAREXEL INTERNATIONAL CORPORATION.
      • 12.1.12.1 Company overview
      • 12.1.12.2 Service benchmarking
      • 12.1.12.3 Financial performance
      • 12.1.12.4 Strategic initiatives
      • 12.1.12.5 SWOT Analysis
    • 12.1.13 BIOCLINICA, INC.
      • 12.1.13.1 Company overview
      • 12.1.13.2 Service benchmarking
      • 12.1.13.3 Financial performance
      • 12.1.13.4 Strategic initiatives
      • 12.1.13.5 SWOT Analysis
    • 12.1.14 WIPRO
      • 12.1.14.1 Company overview
      • 12.1.14.2 Service benchmarking
      • 12.1.14.3 Financial performance
      • 12.1.14.4 Strategic initiatives
      • 12.1.14.5 SWOT Analysis
    • 12.1.15 UNITED BIOSOURCE LLC
      • 12.1.15.1 Company overview
      • 12.1.15.2 Service benchmarking
      • 12.1.15.3 Financial performance
      • 12.1.15.4 Strategic initiatives
      • 12.1.15.5 SWOT Analysis
    • 12.1.16 FMD K&L (CLINCHOICE)
      • 12.1.16.1 Company overview
      • 12.1.16.2 Service benchmarking
      • 12.1.16.3 Financial performance
      • 12.1.16.4 Strategic initiatives
      • 12.1.16.5 SWOT Analysis

Chapter 13 Winning Strategies

  • 13.1 Key Winning/Scoring Criteria
    • 13.1.1 BY Categories
      • 13.1.1.1 Pharmaceuticals
      • 13.1.1.2 Biotech companies
      • 13.1.1.3 Medical device companies
  • 13.2 Key Vendor Selection Factors
    • 13.2.1 BY Category
    • 13.2.2 By Company Size
      • 13.2.2.1 Key Takeways

Chapter 14 Switching Cost Analysis

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of Abbreviation
  • TABLE 3 Types of ADRs
  • TABLE 4 Adverse Drug Events (ADEs) in hospitals
  • TABLE 5 Pharmacovigilance outsourcing services insights
  • TABLE 6 List of regulations, by country
  • TABLE 7 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
  • TABLE 8 Case management costing by year
  • TABLE 9 Price by case processing volume
  • TABLE 10 Subscription services for medical manuscript writing
  • TABLE 11 Total literature searches (2013-2022)
  • TABLE 12 Instances of failed phase I clinical trials for COVID-19 vaccine
  • TABLE 13 Recruiting phase II clinical trials for oncology
  • TABLE 14 Outsourcing trend observed in pharmaceutical companies
  • TABLE 15 Recent Market Events
  • TABLE 16 List of Major Deals & Acquisitions
  • TABLE 17 North America pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 18 North America pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 19 North America pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 20 North America pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 21 North America pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 22 North America pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 23 U.S. pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 24 U.S. pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 25 U.S. pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 26 U.S. pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 27 U.S. pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 28 U.S. pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 29 Canada pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 30 Canada pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 31 Canada pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 32 Canada pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 33 Canada pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 34 Canada pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 35 Europe pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 36 Europe pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 37 Europe pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 38 Europe pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 39 Europe pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 40 Europe pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 41 UK pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 42 UK pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 43 UK pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 44 UK pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 45 UK pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 46 UK pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 47 Germany pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 48 Germany pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 49 Germany pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 50 Germany pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 51 Germany pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 52 Germany pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 53 France pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 54 France pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 55 France pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 56 France pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 57 France pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 58 France pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 59 Italy pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 60 Italy pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 61 Italy pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 62 Italy pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 63 Italy pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 64 Italy pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 65 Spain pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 66 Spain pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 67 Spain pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 68 Spain pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 69 Spain pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 70 Spain pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 71 Russia pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 72 Russia pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 73 Russia pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 74 Russia pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 75 Russia pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 76 Russia pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 77 Denmark pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 78 Denmark pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 79 Denmark pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 80 Denmark pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 81 Denmark pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 82 Denmark pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 83 Norway pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 84 Norway pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 85 Norway pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 86 Norway pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 87 Norway pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 88 Norway pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 89 Sweden pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 90 Sweden pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 91 Sweden pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 92 Sweden pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 93 Sweden pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 94 Sweden pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 95 Asia Pacific pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 96 Asia Pacific pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 97 Asia Pacific pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 98 Asia Pacific pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 99 Asia Pacific pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 100 Asia Pacific pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 101 Japan pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 102 Japan pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 103 Japan pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 104 Japan pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 105 Japan pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 106 Japan pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 107 China pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 108 China pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 109 China pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 110 China pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 111 China pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 112 China pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 113 India pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 114 India pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 115 India pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 116 India pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 117 India pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 118 India pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 119 Australia pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 120 Australia pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 121 Australia pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 122 Australia pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 123 Australia pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 124 Australia pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 125 Thailand pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 126 Thailand pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 127 Thailand pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 128 Thailand pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 129 Thailand pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 130 Thailand pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 131 South Korea pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 132 South Korea pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 133 South Korea pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 134 South Korea pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 135 South Korea pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 136 South Korea pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 137 Latin America pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 138 Latin America pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 139 Latin America pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 140 Latin America pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 141 Latin America pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 142 Latin America pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 143 Brazil pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 144 Brazil pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 145 Brazil pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 146 Brazil pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 147 Brazil pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 148 Brazil pharmacovigilance market, by end use, 2017- 2030 (USD Million
  • TABLE 149 Mexico pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 150 Mexico pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 151 Mexico pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 152 Mexico pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 153 Mexico pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 154 Mexico pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 155 Argentina pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 156 Argentina pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 157 Argentina pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 158 Argentina pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 159 Argentina pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 160 Argentina pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 161 MEA pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 162 MEA pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 163 MEA pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 164 MEA pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 165 MEA pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 166 MEA pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 167 South Africa pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 168 South Africa pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 169 South Africa pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 170 South Africa pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 171 South Africa pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 172 South Africa pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 173 Saudi Arabia pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 174 Saudi Arabia pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 175 Saudi Arabia pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 176 Saudi Arabia pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 177 Saudi Arabia pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 178 Saudi Arabia pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 179 UAE pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 180 UAE pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 181 UAE pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 182 UAE pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 183 UAE pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 184 UAE pharmacovigilance market, by end use, 2018 - 2030 (USD Million)
  • TABLE 185 Kuwait pharmacovigilance market, by service provider, 2018 - 2030 (USD Million)
  • TABLE 186 Kuwait pharmacovigilance market, by product life cycle, 2018 - 2030 (USD Million)
  • TABLE 187 Kuwait pharmacovigilance market, by type, 2018 - 2030 (USD Million)
  • TABLE 188 Kuwait pharmacovigilance market, by therapeutic area, 2018 - 2030 (USD Million)
  • TABLE 189 Kuwait pharmacovigilance market, by process flow, 2018 - 2030 (USD Million)
  • TABLE 190 Kuwait pharmacovigilance market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Pharmacovigilance market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Primary interviews in North America
  • Fig. 6 Primary interviews in Europe
  • Fig. 7 Primary interviews in APAC
  • Fig. 8 Primary interviews in Latin America
  • Fig. 9 Primary interviews in MEA
  • Fig. 10 Market research approaches
  • Fig. 11 Value-chain-based sizing & forecasting
  • Fig. 12 QFD modeling for market share assessment
  • Fig. 13 Market formulation & validation
  • Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
  • Fig. 15 Market Snapshot
  • Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
  • Fig. 17 Segment Snapshot (Type & Therapeutic Area)
  • Fig. 18 Segment Snapshot (Process Flow & End Use))
  • Fig. 19 Competitive Landscape Snapshot
  • Fig. 20 Penetration & growth prospect mapping
  • Fig. 21 Pharmacovigilance market dynamics
  • Fig. 22 Porter's five force model
  • Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
  • Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
  • Fig. 25 PV department
  • Fig. 26 PV organization structure
  • Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
  • Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
  • Fig. 29 Average % of drug safety budget contributed by function at a global level
  • Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
  • Fig. 31 Clinical trial cost by phase (%)
  • Fig. 32 Selected clinical trials costs based on technology
  • Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
  • Fig. 34 The average monthly cost of illness due to ADRs
  • Fig. 35 Medical Writers Employers by Industry
  • Fig. 36 Trending topics on social media (2017)
  • Fig. 37 ADR detection and from social media data
  • Fig. 38 Common literature automation tool flow
  • Fig. 39 Automation processes in PV
  • Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
  • Fig. 41 The three-step process to compute signal statistics from search log using big data
  • Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
  • Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
  • Fig. 44 Medical writing market outlook, 2022 (USD Million)
  • Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
  • Fig. 46 Global medical safety review market, 2018 - 2030 (USD Million)
  • Fig. 47 Pharmacovigilance market: Product life cycle movement analysis
  • Fig. 48 Pharmacovigilance market product life cycle dashboard
  • Fig. 49 Global Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 50 Global Phase I market, 2018 - 2030 (USD Million)
  • Fig. 51 Global Phase II market, 2018 - 2030 (USD Million)
  • Fig. 52 Global Phase III market, 2018 - 2030 (USD Million)
  • Fig. 53 Adverse events reported in FAERS system, 2019-2022
  • Fig. 54 Global Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 55 Pharmacovigilance market: Service provider movement analysis
  • Fig. 56 Pharmacovigilance Service provider dashboard
  • Fig. 57 Global In-house market, 2018 - 2030 (USD Million)
  • Fig. 58 Global contract outsourcing market, 2018 - 2030 (USD Million)
  • Fig. 59 Pharmacovigilance market: Type movement analysis
  • Fig. 60 Pharmacovigilance type dashboard
  • Fig. 61 Global spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 62 Global intensified ADR reporting market, 2018 - 2030 (USD Million)
  • Fig. 63 Global targeted spontaneous reporting market, 2018 - 2030 (USD Million)
  • Fig. 64 Global CEM market, 2018 - 2030 (USD Million)
  • Fig. 65 Global EHR mining market, 2018 - 2030 (USD Million)
  • Fig. 66 Pharmacovigilance market: Process flow movement analysis
  • Fig. 67 Pharmacovigilance market process flow dashboard
  • Fig. 68 Global case data management market, 2018 - 2030 (USD Million)
  • Fig. 69 Global case logging market, 2018 - 2030 (USD Million)
  • Fig. 70 Global case data analysis market, 2018 - 2030 (USD Million)
  • Fig. 71 Global medical reviewing and reporting market, 2018 - 2030 (USD Million)
  • Fig. 72 Global signal detection market, 2018 - 2030(USD Million)
  • Fig. 73 Global adverse event logging market, 2018 - 2030 (USD Million)
  • Fig. 74 Global adverse event analysis market, 2018 - 2030 (USD Million)
  • Fig. 75 Global adverse event review & reporting market, 2018 - 2030 (USD Million)
  • Fig. 76 Global risk management system market, 2018 - 2030 (USD Million)
  • Fig. 77 Global Risk Evaluation System market, 2018 - 2030 (USD Million)
  • Fig. 78 Global risk mitigation system market, 2018 - 2030 (USD Million)
  • Fig. 79 Pharmacovigilance market: Therapeutic area movement analysis
  • Fig. 80 Pharmacovigilance market therapeutic area dashboard
  • Fig. 81 Global oncology market, 2018 - 2030 (USD Million)
  • Fig. 82 Global neurology market, 2018 - 2030 (USD Million)
  • Fig. 83 Global cardiology market, 2018 - 2030 (USD Million)
  • Fig. 84 Global respiratory systems market, 2018 - 2030 (USD Million)
  • Fig. 85 Global others market, 2018 - 2030 (USD Million)
  • Fig. 86 Pharmacovigilance market: End-use movement analysis
  • Fig. 87 Pharmacovigilance market end-use dashboard
  • Fig. 88 Global pharmaceuticals market, 2018 - 2030 (USD Million)
  • Fig. 89 Global biotechnology companies' market, 2018 - 2030 (USD Million)
  • Fig. 90 Global medical device manufacturers market, 2018 - 2030 (USD Million)
  • Fig. 91 Global others market, 2018 - 2030 (USD Million)
  • Fig. 92 Regional market place: Key takeaways
  • Fig. 93 North America pharmacovigilance market, 2018- 2030 (USD Million)
  • Fig. 94 U.S. key country dynamics
  • Fig. 95 U.S. key country dynamics
  • Fig. 96 U.S. pharmacovigilance market, 2018 - 2030(USD Million)
  • Fig. 97 Canada key country dynamics
  • Fig. 98 Canada key country dynamics
  • Fig. 99 Canada pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 100 Europe pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 101 UK key country dynamics
  • Fig. 102 UK key country dynamics
  • Fig. 103 UK pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 104 Germany key country dynamics
  • Fig. 105 Germany key country dynamics
  • Fig. 106 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 107 France key country dynamics
  • Fig. 108 France key country dynamics
  • Fig. 109 France pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 110 Italy key country dynamics
  • Fig. 111 Italy key country dynamics
  • Fig. 112 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 113 Spain key country dynamics
  • Fig. 114 Spain key country dynamics
  • Fig. 115 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 116 Russia key country dynamics
  • Fig. 117 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 118 Denmark key country dynamics
  • Fig. 119 Denmark key country dynamics
  • Fig. 120 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
  • Fig. 121 Norway key country dynamics
  • Fig. 122 Norway key country dynamics
  • Fig. 123 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
  • Fig. 124 Sweden key country dynamics
  • Fig. 125 Sweden key country dynamics
  • Fig. 126 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030, (USD Million)
  • Fig. 127 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 130 Japan pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 131 China key country dynamics
  • Fig. 132 China key country dynamics
  • Fig. 133 China pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 134 India key country dynamics
  • Fig. 135 India key country dynamics
  • Fig. 136 India pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 139 Australia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 140 Thailand key country dynamics
  • Fig. 141 Thailand key country dynamics
  • Fig. 142 Thailand pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 145 South Korea pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 146 Latin America pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 149 Brazil pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 150 Mexico key country dynamics
  • Fig. 152 Mexico pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 155 Argentina pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 156 MEA pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 159 South Africa pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 162 Saudi Arabia pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 163 UAE key country dynamics
  • Fig. 164 UAE key country dynamics
  • Fig. 165 UAE pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 167 Kuwait pharmacovigilance market, 2018 - 2030 (USD Million)
  • Fig. 168 Market participant categorization
  • Fig. 169 Company market position analysis
  • Fig. 170 Estimated company market share analysis, 2022 (%)
  • Fig. 171 SWOT - Accenture
  • Fig. 172 SWOT - Linical Americas
  • Fig. 173 SWOT - IQVIA
  • Fig. 174 SWOT - Cognizant
  • Fig. 175 SWOT - Laboratory Corporation of America Holdings
  • Fig. 176 SWOT - IBM Corporation
  • Fig. 177 SWOT - ArisGlobal
  • Fig. 178 SWOT - ICON plc
  • Fig. 179 SWOT - Capgemini
  • Fig. 180 SWOT - ITClinical
  • Fig. 181 SWOT - Take Solutions
  • Fig. 182 SWOT - Parexel International Corporation
  • Fig. 183 SWOT - Clario
  • Fig. 184 SWOT - Wipro
  • Fig. 185 SWOT - United BioSource LLC
  • Fig. 186 SWOT - FMD K&L
  • Fig. 187 Commonly outsourced PV activities
  • Fig. 188 Vendor selection criteria